Literature DB >> 25062524

Assessing neonates for neonatal abstinence: are you reliable?

Karen C DʼApolito1.   

Abstract

Nationally, there has been a steady increase in the number of infants born with neonatal abstinence syndrome or drug withdrawal. Many of these infants remain in the hospital because their signs of withdrawal require pharmacologic management. The length of hospital stay can range from 1 week to several months depending on the severity of withdrawal. One way to decrease the length of stay and reduce the cost of care is to discharge the infant from the hospital sooner. To discharge infants sooner, their neonatal abstinence syndrome must be accurately assessed so that appropriate pharmacologic management can be administered. One way to increase the accuracy of assessing withdrawal signs is to implement an interobserver reliability protocol. This approach will allow healthcare professionals to gain consistency and accuracy in assessing infants for signs of withdrawal that may facilitate earlier discharge from the hospital.

Entities:  

Mesh:

Year:  2014        PMID: 25062524     DOI: 10.1097/JPN.0000000000000056

Source DB:  PubMed          Journal:  J Perinat Neonatal Nurs        ISSN: 0893-2190            Impact factor:   1.638


  2 in total

1.  Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.

Authors:  Jonathan M Davis; Jeffrey Shenberger; Norma Terrin; Janis L Breeze; Mark Hudak; Elisha M Wachman; Peter Marro; Erica L Oliveira; Karen Harvey-Wilkes; Adam Czynski; Barbara Engelhardt; Karen D'Apolito; Debra Bogen; Barry Lester
Journal:  JAMA Pediatr       Date:  2018-08-01       Impact factor: 16.193

2.  Development and application of a primer and reference assessment tool for neonatal abstinence syndrome: A phase I pilot study.

Authors:  Ekaterina Burduli; Crystal Lederhos Smith; Phoebe Tham; Maureen Shogan; Ron Kim Johnson; Sterling M McPherson
Journal:  Contemp Clin Trials Commun       Date:  2019-12-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.